Editorial Board

Editor-in-Chief

Jai Radhakrishnan, MD, Columbia University College of Physicians and Surgeons, New

York, New York, United States

Deputy Editor

Sumit Mohan, MD, Columbia University College of Physicians and Surgeons, New

York, New York, United States

Executive Editor

Radha McLean, MA, Columbia University, New York, New York, United States

Associate Editors

Stephen Pastan, MD, Emory University School of Medicine, Atlanta, Georgia, United

States

Jacob Stevens, MD, Columbia University College of Physicians and Surgeons, Division

of Nephrology, New York, New York, United States

Social Media Editor

Shayan Shirazian, MD, Columbia University College of Physicians and Surgeons, New

York, New York, United States

Statistical Reviewers

Magdalene Assimon, PharmD, PhD, University of North Carolina, Kidney Center,

Chapel Hill, North Carolina, United States

Brad Astor, PhD, MPH, University of Wisconsin School of Medicine and Public Health,

Depts. of Medicine & Population Health Sciences, Madison, Wisconsin, United States

Bo Bibby, PhD, University of Aarhus Section of Biostatistics, Aarhus, Denmark

Zhezhen Jin, PhD, Columbia University, Department of Biostatistics, Mailman School of

Public Health, New York, New York, United States

Kristen King, MPH, Columbia University Medical Center, Division of Nephrology, New

York, New York, United States

Sudeshna Paul, PhD, MS, Emory University, School of Nursing, Atlanta, Georgia, United

States

Kam-Fai Wong, PhD, National University of Kaohsiung, Institute of Statistics,

Kaohsiung, Taiwan

Xiaonan Xue, PhD, Albert Einstein College of Medicine, Epidemiology & Population

Health, Bronx, New York, United States

Jingyan Yang, DrPH, MHS, Columbia University, Mailman School of Public Health,

New York, New York, United States

Rebecca Zhang, MS, Emory University, Department of Biostatistics, Rollins School of

Public Health, Atlanta, Georgia, United States

Editorial Board

Rajiv Agarwal, MD, Indiana University School of Medicine, Indianapolis, Indiana,

United States

John Asplin, MD, LithoLink Corp, Chicago, Illinois, United States

Sean Bagshaw, MD, University of Alberta, Edmonton, Alberta, Canada

Joanne Bargman, MD, University of Toronto Faculty of Medicine, Toronto, Ontario,

Canada

Laurence Beck, Jr., MD, PhD, Boston University School of Medicine, Boston,

Massachusetts, United States

Srinivasan Beddhu, MD, VA Salt Lake City Health Care System, Salt Lake City, Utah,

United States

Detlef Bockenhauer, MD, PhD, University College London, London, United Kingdom

Andrew S. Bomback, MD, Columbia University College of Physicians and Surgeons,

New York, New York, United States

Barry Brenner, MD, Harvard Medical School, Boston, Massachusetts, United States

Pietro Canetta, MD, Columbia University Medical Center, New York, New York, United

States

Bryan Carmody, MD, MPH, Children's Hospital of The King's Daughters, Norfolk,

Virginia, United States

Jorge Cerda, MD, ALBANY MEDICAL COLLEGE, Albany, New York, United States

Terence Cook, MD, Imperial College London, London, United Kingdom

Rosanna Coppo, MD, Regina Margherita Children's Hospital, Torino, Italy

Steven D. Crowley, MD, Duke University, Durham, North Carolina, United States

Kent Doi, MD, PhD, The University of Tokyo, Bunkyo-Ku, Tokyo, Japan

Murray Epstein, MD, University of Miami School of Medicine, Miami, Florida, United

States

Alton Farris, MD, EMORY UNIVERSITY, Atlanta, Georgia, United States

John Feehally, MD, University Hospitals of Leicester, The John Walls Renal Unit,

Leicestershire, United Kingdom

Frederic O. Finkelstein, MD, YALE UNIVERSITY SCHOOL OF MEDICINE, New

Haven, Connecticut, United States

Ali Gharavi, MD, Columbia University College of Physicians and Surgeons, New York,

New York, United States

Richard Glassock, MD, David Geffen School of Medicine at UCLA, Department of

Medicine, Laguna Niguel, California, United States

David Goldsmith, MD, Guy's and Saint Thomas' NHS Foundation Trust, London, United

Kingdom

Stuart L. Goldstein, MD, Cincinnati Children's Hospital Medical Center, Cincinnati,

Ohio, United States

Orlando Gutierrez, MD, University of Alabama at Birmingham, Birmingham, Alabama,

United States

David Harris, MD, The University of Sydney, Sydney, Australia

Salim Hayek, MD, UNIVERSITY OF MICHIGAN, Ann Arbor, Michigan, United States

Jonathan Hogan, MD, University of Pennsylvania Perelman School of Medicine,

Philadelphia, Pennsylvania, United States

Kitty Jager, MD, PhD, Academic Medical Center, Amsterdam, Netherlands

J. Charles Jennette, MD, University of North Carolina at Chapel Hill, Chapel Hill, North

Carolina, United States

Vivekanand Jha, MD, DM, The George Institute for Global Health, New Delhi, India

Kamyar Kalantar-Zadeh, MD, MPH, PhD, University of California Irvine, Irvine,

California, United States

Clifford Kashtan, MD, University of Minnesota Medical School Twin Cities,

Minneapolis, Minnesota, United States

Donald E. Kohan, MD, PhD, University of Utah School of Medicine, Salt Lake City,

Utah, United States

Csaba P. Kovesdy, MD, University of Tennessee Health Science Center, Memphis,

Tennessee, United States

Charmaine E. Lok, MD, University of Toronto, Toronto, Ontario, Canada

Nicolaos E. Madias, MD, Tufts University School of Medicine, Division of Nephrology,

Medford, Massachusetts, United States

Glen Markowitz, MD, Columbia University College of Physicians and Surgeons, New

York, New York, United States

Christopher W. McIntyre, MD, PhD, Western University, London, Ontario, Canada

Ravindra L. Mehta, MB, BS, MD, DM, University of California San Diego, La Jolla,

California, United States

Thomas Nickolas, MD, MS, Columbia University Medical Center, New York, New

York, United States

Chirag Parikh, MD, PhD, YALE UNIVERSITY, New Haven, Connecticut, United States

Rachel Patzer, PhD, MPH, Emory University School of Medicine, Atlanta, Georgia,

United States

Mark Perazella, MD, YALE UNIVERSITY SCHOOL OF MEDICINE, New Haven,

Connecticut, United States

John Prowle, MD, Queen Mary University of London, London, United Kingdom

Hamid Rabb, MD, JOHNS HOPKINS UNIVERSITY, Baltimore, Maryland, United

States

Dominick Raj, MD, GEORGE WASHINGTON UNIVERSITY, Washington, District of

Columbia, United States

Pierre Ronco, MD, PhD, Sorbonne University Pierre and Marie Curie Campus, Paris,

France

Mitchell H. Rosner, MD, UNIVERSITY OF VIRGINIA HEALTH SYSTEM,

Charlottesville, Virginia, United States

Brad Rovin, MD, OHIO STATE UNIVERSITY, Columbus, Ohio, United States

Minnie Sarwal, MD, University of California San Francisco, San Francisco, California,

United States

Judith Savige, MD, Peking University, Beijing, China

Sanjeev Sethi, MD, PhD, MAYO CLINIC, Rochester, Minnesota, United States

Robert N. Sladen, MD, Columbia University College of Physicians and Surgeons, New

York, New York, United States

Stefan Somlo, MD, YALE UNIVERSITY SCHOOL OF MEDICINE, New Haven,

Connecticut, United States

Michael Stokes, MD, Columbia University Department of Pathology and Cell Biology,

New York United States

Kouichi Tamura, MD, Yokohama City University, Yokohama, Japan

Bekir Tanriover, MD, MPH, UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL

CENTER, Dallas, Texas, United States

Visith Thongboonkerd, MD, Mahidol University Faculty of Medicine Siriraj Hospital,

Bangkok, Thailand

Ashita Tolwani, MD, University of Alabama at Birmingham, Birmingham, Alabama,

United States

Tushar Vachharajani, MD, Wake Forest University School of Medicine, Winston-Salem,

North Carolina, United States

Patrick Walker, MD, Nephropath, Little Rock, Arkansas, United States

Jan J. Weening, MD, Tergooi Hospitals Campus Blaricum, Blaricum, Netherlands

Alexander Yevzlin, MD, University of Wisconsin Madison, Madison, Wisconsin, United

States

July 2019 Volume 4, Issue 7, Supplement, S1-S438

ISN World Congress of Nephrology (WCN) Abstracts

12 April 2019 - 15 April 2019

Open Access

Receive New Issues & Articles: Email Alert | RSS Feed

Search within this issue

Showing: 10-20

< Prev

...

10

11

12

13

14

15 16

17

18

19

20

...

Next >

Select all articles on page to then view abstracts, export citations, email, or add to reading list

Select All View abstracts of articles selected in the list View Abstracts | Export citations of

articles selected in the list Export Citations | Email articles selected in the list Email a Colleague

Add the articles selected in the list to your reading list | Add to Reading List

o MON-013 A CASE OF MEMBRANOUS NEPHROPATHY THAT

DEVELOPPED AFTER USE OF NIVOLUMAB

K. WAKABAYASHI, S. Yamamoto, N. Ikeda, Y. Kusunoki, M. Takeji

S308

Published in issue: July 2019

Full-Text HTMLPDF

o MON-014 URINARY MEMBRANE ATTACK COMPLEX (UMAC): A

PROGNOSIS BIOMARKER FOR TREATMENT RESPONSE IN FOCAL

AND SEGMENTAL GLOMERULOSCLEROSIS (FSGS)?

J.C. Trimino Monroy MD, R. Valdez Ortiz MD PhD, M. Perez-Navarro PhD, L.J.

Paniagua Flores, E. Pedraza Rojas, M.V. Soto Abraham MD PhD, Z. Medina

Avila PhD, G. Gutierrez Reyes PhD

S308–S309

Published in issue: July 2019

Full-Text HTMLPDF

o

MON-015 RENAL BIOPSY IN MONGOLIA: GLOMERULAR DISEASE

FEATURES

S. ADIYA, U.O. Namhai, E. Bavuujab, B. Baatarkhuu, K. Erdenedoo, K.

Damdinsuren, A. Jamba, N. Dorj, E. Mendbayar, C. Dorj

S309

Published in issue: July 2019

Full-Text HTMLPDF

o MON-016 A RETROSPECTIVE STUDY ON CLINICOPATHOLOGICAL

DIAGNOSIS OF NEPHROTIC SYNDROME – A SINGLE CENTRE

EXPERIENCE IN SRI LANKA

D. BASNAYAKE, B. Mahanama, B. Thangarajah, M. Wazil, N. Nanayakkara, N.

Ratnatunga

S309

Published in issue: July 2019

Full-Text HTMLPDF

o MON-017 SENSITIVITY AND SPECIFICITY OF SERUM PLA2

RECEPTOR ANTIBODIES IN DIAGNOSIS OF PRIMARY

MEMBRANOUS NEPHROPATHY

R.S. Bonu MD, V. deepesh

S310

Published in issue: July 2019

Full-Text HTMLPDF

o MON-018 LUPUS HAS HIGHER GLOMERULAR AND TUBULAR

PATHOLOGY SEVERITY INDEX THAN NON-LUPUS NEPHROTIC

SYNDROME

R. DUARSA, N.W. Winarti, I.G.R. Widiana

S310

Published in issue: July 2019

Full-Text HTMLPDF

o MON-019 BETA-3-INTEGRIN STAINING IN KIDNEY BIOPSY AND

CORRELATION WITH RESPONSE TO CALCINEURIN INHIBITORS IN

STEROID RESISTANT NEPHROTIC SYNDROME

S. Govindan MD, K.L. Gupta, S. Singh, R. Nada, R. Ramachandran, A. Kumar,

V. Sharma, H.S. Kohli, V. Jha

S310–S311

Published in issue: July 2019

Full-Text HTMLPDF

o MON-020 MULTIPLE POTENTIAL AETIOLOGIES OF

MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS IN A

COMPLEX PATIENT

E. HOURN, J. Kurtkoti

S311–S312

Published in issue: July 2019

Full-Text HTMLPDF

o MON-021 IMMUNOHISTOLOGICAL SPECTRUM OF CRESCENTIC

GLOMERLONEPHRITIS, A SINGLE CENTER STUDY IN

BANGLADESH

J. ISLAM

S312

Published in issue: July 2019

Full-Text HTMLPDF

o MON-022 STEROID RESISTANCE IN CHILDHOOD NEPHROTIC

SYNDROME IN MAPUTO, MOZAMBIQUE

S. KAKAR, K. Faktor, Y. Monteiro, W.C. Buck, S. Taunde, E. Gonzaga, D.

Puliyanda

S312

Published in issue: July 2019

Full-Text HTMLPDF

o MON-023 HYPOKALEMIC NEPHROPATHY IN NEPHROTIC

SYNDROME PATIENT

I.M.R. PUTRA, R. Duarsa, N. Paramita Ayu, W. Winarti, K. Suwitra, I.G.R.

Widiana

S312–S313

Published in issue: July 2019

Full-Text HTMLPDF

o MON-024 UNUSUAL PRESENTATION OF DENSE DEPOSIT DISEASE.

P. RASTOGI, M. Obediat, D. Holanda G

S313–S314

Published in issue: July 2019

Full-Text HTMLPDF

o MON-025 Toll-like receptors in glomerulonephritis

Q. REN

S314

Published in issue: July 2019

Full-Text HTMLPDF

o MON-026 A THERAPEUTIC RECOMMENDATION FOR

MEMBRANOUS NEPHROPATHY ASSOCIATED WITH CHRONIC

GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC PERIPHERAL

BLOOD STEM CELL TRANSPLANTATION

H. BEPPU, Y. Arai, I. Kondo, S. Shioji, E. Sakamoto, Y. Minani, D. Katagiri, M.

Tada, F. Hinoshita

S315

Published in issue: July 2019

Full-Text HTMLPDF

o MON-027 LONG TERM FOLLOW UP OF METHYLPREDNISOLONE

PULSE AND AUTOLOGOUS SVF THERAPY IN SEVERE IgA

NEPHROPAHTY

H. YUN, B.S. Cho, S. Jung, H. Lee, D.Y. Kim

S315

Published in issue: July 2019

Full-Text HTMLPDF

o MON-028 PATHOLOGICALLY PROVEN COMPLETE CURE OF

IDIOPATHIC MEMBRANOUS GLOMERULONEPHRITIS BY

METHYLPREDNISOLONE PULSE THERAPY

H. YUN, B.S. Cho, S. Jung, S.K. Ha, H.I. Ko, K.W. Jung, H.S. Lee

S315

Published in issue: July 2019

Full-Text HTMLPDF

o MON-029 PATTERN OF GLOMERULONEPHRITIS IN BANGLADESH-

A SINGLE CENTER STUDY AT A TERTIARY CARE HOSPITAL

R.D. Gupta, A.A. Mamun, S.M. Morshed, G.C. Roy, H.M.N. Ahsan

S316

Published in issue: July 2019

Full-Text HTMLPDF

o MON-030 AUTO-IMMUNE PHENOMENA IN TREATED HIV - A RARE

CASE OF ANCA VASCULITIS

K. HEGERTY, S. Jahan, A. Redmond, D. Ranganathan

S316

Published in issue: July 2019

Full-Text HTMLPDF

o MON-031 OLDER INDIVIDUALS UNDERGOING NATIVE KIDNEY

BIOPSIES: TREND OVER 10 YEARS IN AN URBAN SOUTHEAST

ASIAN CENTER

H. Huang, C.C. Lim, Y.M. Chin, W.L. Teng, M. Foo, K.T. Woo

S316–S317

Published in issue: July 2019

Full-Text HTMLPDF

o

MON-032 RENAL BIOPSY FINDINGS IN LUPUS NEPHRITIS AND

THEIR CORRELATION WITH CLINICAL AND BIOCHEMICAL

PARAMETERS

D.P. KAR, V.C. Ganiger

S317

Published in issue: July 2019

Full-Text HTMLPDF

o MON-033 ETIOLOGY AND OUTCOME OF PULMONARY RENAL

SYNDROME; RETROSPECTIVE ANALYSIS FROM A TERTIARY

CARE CENTER

F.G. KHAN

S317

Published in issue: July 2019

Full-Text HTMLPDF

o MON-034 A case of frequent relapse minimal change nephrotic syndrome

with steroid-induced psychiatric syndromes treated by a low-dose and short-

term steroid therapy in combination with cyclosporine

I. Kondo, Y. Arai, S. Shioji, H. Beppu, S. Emi, Y. Mitani, D. Katagiri, M. Tada,

F. Hinoshita

S317–S318

Published in issue: July 2019

Full-Text HTMLPDF

o MON-035 CLINICAL PRESENTATION, TREATMENT AND OUTCOME

OF IMMUNOGLOBULIN A NEPHROPATHY WITH CRESCENTS IN AN

URBAN SOUTHEAST ASIAN COHORT

C. LIM, J. Choo, K.T. Woo, C.M. Chan, M. Foo, S. Baikunje

S318

Published in issue: July 2019

Full-Text HTMLPDF

o MON-036 PROGNOSIS OF SEVERE LUPUS NEPHRITIS PATIENTS

TREATED WITH CONTINUOUS RENAL REPLACEMENT THERAPY

D. Liu, Y. Chen, Y. Tu, L. Zhang, X. Yang, H. Xie, Z.H. Liu

S318

Published in issue: July 2019

Full-Text HTMLPDF

o MON-037 A RARE CASE: FAMILIAL MULTICENTRIC OSTEOLYSIS

WITH NEPHROPATHY TREATED WITH TACROLIMUS

D. MAXTED, C. Upton, T. McCulloch, J. Evans

S319

Published in issue: July 2019

Full-Text HTMLPDF

o MON-038 ANTI-GBM NEPHRITIS WITH NEPHROTIC SYNDROME

G. MCDONALD, B. Chacko

S319–S320

Published in issue: July 2019

Full-Text HTMLPDF

o MON-039 SMALL KIDNEY SIZE RELATIVE TO BODY MASS IS A

RISK FACTOR FOR RENAL FUNCTION DETERIORATION IN IGA

NEPHROPATHY PATIENTS

Y. Nam, S.Y. Lee, S. Lee, Y.S. Joo, K.H. Nam, J.T. Park

S320

Published in issue: July 2019

Full-Text HTMLPDF

o MON-040 CLINICAL PROFILE & OUTCOME OF IGA NEPHROPATHY

PATIENTS

A. Pasari, M. Balwani, M. Patel, M. trivedi

S320

Published in issue: July 2019

Full-Text HTMLPDF

o MON-041 Renal Biopsy Profile from Central Part of India

M. Balwani, A. Pasari, M. Patel

S320–S321

Published in issue: July 2019

Full-Text HTMLPDF

o

MON-042 Fixed Dose Steroids as Part of Immunosuppressive Therapy in

Idiopathic Membranous Nephropathy A Single Centre Experience)

G. RANA, T. Sherazee, M. El Kossi, M. El Kossi

S321

Published in issue: July 2019

Full-Text HTMLPDF

o MON-043 Characteristics, immunosuppression and progression in IgA

nephropathy with hyperuricemia

Y. RUAN, F. Hong, J. Wu, M. Lin, C. Wang, F. Lian, F. Cao

S321–S322

Published in issue: July 2019

Full-Text HTMLPDF

o MON-044 PREDICTION OF OUTCOMES OF RAPIDLY PROGRESSIVE

GLOMERULONEPHRITIS

J. Sandhu

S322

Published in issue: July 2019

Full-Text HTMLPDF

o MON-045 CLINICAL PROFILE OF CHILDHOOD NEPHROTIC

SYNDROME AND FOLLOW UP & CHALLENGES OUTCOME AT

NAIVE PAEDIATRIC NEPHROLOGY CLINIC

S. Sharma

S322–S323

Published in issue: July 2019

Full-Text HTMLPDF

o MON-046 POST-STREPTOCOCCAL ACUTE PULMONARY RENAL

SYNDROME

R. SHETTIGAR, J. Schollum, V. Hristova, M. Lau

S323

Published in issue: July 2019

Full-Text HTMLPDF

o MON-047 Monoclonal antibodies: Saviour of the gut vs an agent of kidney

injury!

A. SINGH, R. Powell, P. Boddana, M. Khogali

S323–S324

Published in issue: July 2019

Full-Text HTMLPDF

o MON-048 A new report of glomerulonephritis associated with the use of

Talimogene laherparepvec immunotherapy.

R. Scott, S. Muller, P. Boddana, A. SINGH

S324–S325

Published in issue: July 2019

Full-Text HTMLPDF

o MON-049 Cat-scratch disease manifesting as C3 glomerulonephritis (case

report)

B. Sutu, S.Y. Tio, J. Sasadeusz, M. Finlay, T. Barbour

S325

Published in issue: July 2019

Full-Text HTMLPDF

o MON-050 OUTCOME OF FSGS TREATMENT WITH MMF

T. Umeizudike, J. Awobusuyi, A. Adekoya, M. Amisu

S325

Published in issue: July 2019

Full-Text HTMLPDF

o MON-051 CMV INFECTION IN CHILDREN WITH SYSTEMIC LUPUS

ERYTHEMATEOUS: DESCRIPTION OF 3 CASES

V. VO, T. Hoang

S325

Published in issue: July 2019

Full-Text HTMLPDF

o MON-052 MULTITARGET THERAPY AS RESCUE INDUCTION

THERAPY IN PROLIFERATIVE LUPUS NEPHRITIS. A SINGLE

CENTRE EXPERIENCE IN 10 YEARS

S. YAKOB, S.A. Sharif, H.S. Wong, H.S. Wong

S326

Published in issue: July 2019

Full-Text HTMLPDF

o MON-053 CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF

IgA NEPHROPATHY WITH AKD

J.J. Zhang, Y.Y. Du, Y.F. Wei, D. Yu, Y.L. Wang, X.T. Wang

S326

Published in issue: July 2019

Full-Text HTMLPDF

o MON-054 CLINICOPATHOLOGICAL FEATURES AND PROGNOSIS

ANALYSIS OF 49 CASES WITH CRESCENTIC

GLOMERULONEPHRITIS

Y. Zhong, Q. Zhou

S326–S327

Published in issue: July 2019

Full-Text HTMLPDF

o MON-055 THE GROWING BURDEN OF END STAGE RENAL DISEASE

IN INDONESIA: TEN YEARS OF THE INDONESIAN RENAL

REGISTRY REPORTS

A. ABDURAHMAN, R. Bandiara, R. Supriyadi

S327

Published in issue: July 2019

Full-Text HTMLPDF

o MON-056 Leucine-Rich a-2-Glycoprotein 1 increased Peripheral arterial

occlusive disease risk in end-stage renal disease

Y. Feng-Jung

S327

Published in issue: July 2019

Full-Text HTMLPDF

o MON-057 LOOKING BEYOND COST: FULL COVERAGE FOR

HEMODIALYSIS IN THE PHILIPPINES

J. GARCIA

S327–S328

Published in issue: July 2019

Full-Text HTMLPDF

o MON-058 PREGNANCY IN CHRONIC HEMODIALYSIS PATIENTS :

DIAVERUM CASE REPORTS

I. Helal MD, D. Mousa, M. Barhamein, A. Mitwelli, M. Babiker, S. Alghamdi, M.

Alhomrany, A. AlHarbi

S328

Published in issue: July 2019

Full-Text HTMLPDF

o MON-059 RECOVERY OF RENAL FUNCTION IN DIALYSIS AT

OUTSOURCING CENTERS

I. Helal MD, M. Dujanah, E. Hassan, A. Salah, S. Alghamdi, M. Alhomrany, A.

Alharbi

S328

Published in issue: July 2019

Full-Text HTMLPDF

o MON-060 A SNAPSHOT OF DIALYSIS UPTAKE: THE FEASIBILITY OF

INCREMENTAL HAEMODIALYSIS INITIATION

S. JAHAN, M. Wolley

S328–S329

Published in issue: July 2019

Full-Text HTMLPDF

o MON-061 Association between the ratio of serum eicosapentaenoic acid or

docosahexaenoic acid to arachidonic acid and life expectancy in hemodialysis

patients

H. Kanamori

S329

Published in issue: July 2019

Full-Text HTMLPDF

o MON-062 ANALYSIS OF OXIDATIVE STRESS IN PATIENTS ON

DIALYSIS AND HEMODIALYSIS WITH END-STAGE RENAL DISEASE

J. Cerrillos Gutierrez, V. LERMA

S329

Published in issue: July 2019

Full-Text HTMLPDF

MON-017SENSITIVITY AND SPECIFICITY OF SERUMPLA2 RECEPTOR ANTIBODIES IN DIAGNOSISOF PRIMARY MEMBRANOUS NEPHROPATHYBonu MD, RS*1, deepesh, V2

1manipal hospital, nephrology nephrology, Bangalore, India, 2manipalhospital, manipal hospital, bangalore, India

Introduction: Membranous nephropathy is a common cause ofNephrotic syndrome in adults and often requires a kidney biopsyto make a diagnosis, recent past there is a debate whether PLA2Rantibodies will help in making a diagnosis of primary MGNwithout renal biopsy We carried out a prospective to Study todetermine the association between serum anti-PLA2Rantibody andglomerular staining for PLA2R in Membranous Nephropathy Studydesign : Prospective observational, study duration: May 2016 toMay 2018 Inclusion criteria: Adult Nephrotic syndrome thosewho are aged above 18 years undergoing kidney biopsy at ourhospitalMethods: Material & Methods: Serum for anti-PLA2R antibody wassent prior to kidney biopsy in all subjects. The serum anti- PLA2Rantibodies was tested by Indirect immunofluorescence staining usingvalidated commercial kits(Euroimmun).

The kidney biopsy samples were subjected to light micro-scopy,immunofluorescence testing for the panel of antibodies as perstandard protocol. Subsequently PLA2R staining was done as perstandard protocol in those subjectswho showed features of membranousnephropathyResults: In our study 13 out of 58 subjects who presented withnephrotic syndrome had positive serum anti-PLA2R Ab in samplesanalysed at presentation and prior tokidney biopsy. This account for22.4% of the study subjects, while 45(77.6 %) subjects were negativefor the same.

Of the 13 subjects with positve serum anti-PLA2R Ab, 12 sub-jects had light microscopy and immunofluorescence findings ofMNon kidney biopsy. One subject who had FSGS-NOS type on kidneybiopsyshowed weak positive serum anti-PLA2R antibody.

Among the other 45 subjects who did not have serum anti-PLA2R antibody, there wasan additional 16 subjects who werediagnosed with primary MN and 1 with secondaryMN by kidneybiopsy.

This gives a Sensitivity of 41.38%, Specificity of 96.6%,PositivePredictive Value of 92.31%, Negative Predictive Value of 62.22%anddiagnostic accuracy of 68.97% for the test for diagnosis of MN byanti-PLA2Rantibody Statistical analysis by Cohen's kappa test showed alow agreement betweenserum anti-PLA2R Ab and Kidney biopsy was0.3793 (0.1647 - 0.594).Conclusions: In our study the sensitivity and specificity of PLA2Rantibodies in predicting adiagnosis of primary membranous nephrop-athy (pMN) 42.8% and 96.6% respectively Glomerular PLA2R staininghad a sensitivity of 82.8% for diagnosis of MN and 85.5% for diagnosisof primary MN.

The concordance between serum antibodytesting and glomerularstaining in our study showed only slight agreement as percohen kappaassociation test.

The test for serum anti-PLA2R Ab is useful when it is positive,because it almost always confirms the presence of MN even withoutkidney biopsy, but when the test isnegative, it does not exclude MNsince there were patients with negative antibody test, but histologyshowed primary MN.

We think the serum test results depend on timing ofthe test fromthe disease onset, the activity of disease and the amount of antibodyinthe serum at that point and the testing methodology.

MON-018LUPUS HAS HIGHER GLOMERULAR ANDTUBULAR PATHOLOGY SEVERITY INDEX THANNON-LUPUS NEPHROTIC SYNDROMEDUARSA, R*1, Winarti, NW2, Widiana, IGR1

1School of Medicine Udayana University/Sanglah Hospital, Nephrology,Denpasar, Indonesia, 2School of Medicine Udayana University/SanglahHospital, Pathology, Denpasar, Indonesia

Introduction: Lupus is a multisystemic disease where it influences manyorgans including the kidneys through production of autoantibodies andimmune complex formation which results in proteinuria and nephroticsyndrome. Renal pathology abnormalities may be more severe in lupusinvolvement. The study aimed to compare severity of pathologic lesionsamong compartments in kidney tissue between lupus and non-lupus NS(nephrotic syndrome) patients.Methods: All patients with NS were grouped as lupus and non-lupus, later were biopsied and the cores were stained with Hema-toxylin-Eosin, PAS, Masson’s Trichrome to look at glomerular,tubular, interstitial and vascular involvements. Glomerular abnor-malities including mesangial hypercellularity or mesangial matrixexpansion, endocapiller hypercellularity, wireloops, membranous.Severity was assessed from no abnormality, cellular crescent,fibrocellular crescent, and fibrous crescent/fibrosis. Tubular ab-normalities including early course such as cloudy swelling, vacuo-lization, infiltration of inflammation cells to tubular atrophy, andpresence of casts. Interstitial and vascular abnormalities were scoredaccording to activity, severity and distribution.Results: This study included 50 patients, consisted of 24 (48%)lupus NS (3 males and 21 females) and 26 (52%) non-lupus NS (15males and 11 females), aged 27.04 � 10.83 years with mean SBP123.53 � 16.69 mmHg and DBP 79.56 � 10.19 mmHg. Twenty fourhours urine production was 1895.45 � 1277.36 ml among lupuscompared to 2165.22 � 1421.7 ml in non-lupus. Hemoglobin was10.69 � 2.60 g/dL in lupus compared to 13 � 2.69 g/dL in non-lupus. Creatinine was 1.51 � 1.55 mg/dL in lupus compared to 1.67� 1.69 mg/dL in non-lupus. Twenty four hours proteinexcretion was 5.85 � 5.65 g/24 hour in lupus compared to 3.83 �4.28 g/24 hour in non-lupus. Urine cast was 15 (62.5%) in lupuscompared to 11 (42.3%) in non-lupus. Independent student’s t-testwas conducted to compare severity indexes between lupus and non-lupus NS. There was a significant difference in glomerular severityindex between lupus (5 � 2.17) and non-lupus (3.45 � 2.3); p =0.024.There was a significant difference in tubular severity indexbetween lupus (3.79 � 1.84) and non-lupus (2.32 � 1.7); p = 0.007.There was a significant difference in renal pathology severity indexbetween lupus (12.29 � 4.41) and non-lupus (8.68 � 3.99) ; p =0.006.Conclusions: There are significant higher of renal pathology severityindex between lupus nephritis and non-lupus NS composed by higherglomerular and tubular severity index. It may implicate that histo-pathological process difference play an important role in certain clinicaldifferences.

MON-019BETA-3-INTEGRIN STAINING IN KIDNEY BIOPSYAND CORRELATION WITH RESPONSE TOCALCINEURIN INHIBITORS IN STEROIDRESISTANT NEPHROTIC SYNDROMEGovindan MD, S*1, Gupta, KL1, Singh, S2, Nada, R3,Ramachandran, R1, Kumar, A3, Sharma, V4, Kohli, HS1, Jha, V5

1Postgraduate Institute of Medical Education and Research, Nephrology,Chandigarh, India, 2Postgraduate Institute of Medical Education andResearch, Paediatrics, Chandigarh, India, 3Postgraduate Institute of MedicalEducation and Research, Pathology, Chandigarh, India, 4PostgraduateInstitute of Medical Education and Research, Stem cell Research Facility,Chandigarh, India, 5George Institute for Global Health, Executive Director,New Delhi, India

Introduction: Steroid-resistant nephrotic syndrome (SRNS) is diffi-cult to treat and carries a high risk of progression to chronic kidneydisease (CKD). Calcineurin inhibitors (CNIs) are preferentially usedin the treatment of SRNS. Variable response to treatment, the risk ofnephrotoxicity and high rates of relapse on stopping treatment aremajor concerns with CNIs. Urokinase-type Plasminogen ActivatorReceptor (uPAR) – b3 integrin signaling is involved in the calci-neurin-nuclear factor of activated T cells (NFAT) induced podocyteinjury and hence the antiproteinuric effect of CNIs may be partiallyattributed to its inhibition of uPAR-b3 integrin signaling axis inpodocytes. We looked at the correlation between b3 integrinstaining and CNI response in our cohort of patients to determine ifpatients with positive b3 integrin staining show a favorableresponse to CNIs.

ISN WCN 2019 ABSTRACTS

S310 Kidney International Reports (2019) 4, S1–S437